Skip to content
Business Times – Lifestyle
Author:
Innovent Biologics,Inc
Innovent Announces 2025 Annual Results and Business Updates
March 26, 2026
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
March 23, 2026
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
March 22, 2026
←
Previous Page
1
2